Freestone Grove Partners LP Sarepta Therapeutics, Inc. Transaction History
Freestone Grove Partners LP
- $13.4 Trillion
- Q3 2025
A detailed history of Freestone Grove Partners LP transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 18,515 shares of SRPT stock, worth $348,267. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,515Holding current value
$348,267% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SRPT
# of Institutions
413Shares Held
153MCall Options Held
5.44MPut Options Held
6.09M-
Paul Tudor Jones Tudor Investment Corp Et Al | Stamford, Ct68.8MShares$1.29 Billion0.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$203 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$194 Million0.04% of portfolio
-
State Street Corp Boston, MA5.3MShares$99.8 Million0.0% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.69MShares$50.5 Million0.49% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.65B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...